Stay updated on Nivolumab in Relapsed/Refractory DLBCL Clinical Trial

Sign up to get notified when there's something new on the Nivolumab in Relapsed/Refractory DLBCL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab in Relapsed/Refractory DLBCL Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.1%
    Check dated 2025-04-30T18:10:49.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    Change Detected
    Summary
    The page has undergone significant content changes, including the removal of detailed study information regarding Nivolumab's effectiveness for treating DLBCL and the revision number update from v2.14.4 to v2.15.0.
    Difference
    9%
    Check dated 2025-04-16T13:14:36.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-09T05:54:24.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.2 to version 2.14.3.
    Difference
    0.1%
    Check dated 2025-04-01T22:45:49.000Z thumbnail image
  7. Check
    44 days ago
    Change Detected
    Difference
    0.2%
    Check dated 2025-03-25T13:41:31.000Z thumbnail image
  8. Check
    73 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-02-24T20:25:16.000Z thumbnail image

Stay in the know with updates to Nivolumab in Relapsed/Refractory DLBCL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab in Relapsed/Refractory DLBCL Clinical Trial page.